Technical analyst Salil Sharma is of the view that investors can 'hold' Ranbaxy Laboratories Ltd stock with target of Rs 425.

According to analyst, the interested investors can hold the stock with stop loss of Rs 408.

The stock of the company, on May 26, closed at Rs 414.55 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 538 and a low of Rs 240 on BSE.

Current EPS & P/E ratio stood at 16.19 and 25.57 respectively.

The wholly owned arm of Ranbaxy Laboratories Ltd, Ranbaxy Pharmaceuticals Canada (RPCI), got sanction from Health Canada to sell RAN -Atorvastatin pills in different strengths including 10 mg, 20 mg, 40 mg, and 80 mg in the Canadian Healthcare System.

Atorvastatin is a cholesterol lowering tab that currently has a market size of $1.2 billion in Canada.

As per reports, Ranbaxy Labs has sought the US drug regulator's nod to market a novel medication in the world's major pharmaceutical market, which has been made in a division of its Indian factory which is under control of the US regulator.

Mr. Arun Sawhney, Ranbaxy's president (Global Pharmaceuticals), in its annual report said, "We filed our first abbreviated new drug application (ANDA) in 2009, from Batamandi (Himachal Pradesh) with the USFDA."